{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:41:06Z","timestamp":1787913666045,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00210-024-02954-7","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T01:02:21Z","timestamp":1706058141000},"page":"5233-5240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of levetiracetam and carbamazepine monotherapy in the management of pediatric focal epilepsy: a randomized clinical trial"],"prefix":"10.1007","volume":"397","author":[{"given":"Hadi","family":"Montazerlotfelahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsh","family":"Haj Mohamad Ebrahim Ketabforoush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Tavakol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoudreza","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdieh","family":"Dehghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keihan","family":"Mostafavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Mardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Tajfirooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"issue":"3","key":"2954_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1535-7511.2007.00176.x","volume":"7","author":"BW Abou-Khalil","year":"2007","unstructured":"Abou-Khalil BW (2007) Oxcarbazepine and carbamazepine: expected and unexpected differences and similarities. Epilepsy Currents 7(3):74\u201376","journal-title":"Epilepsy Currents"},{"issue":"e1","key":"2954_CR2","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1136\/ejhpharm-2018-001616","volume":"27","author":"MM Aguilera","year":"2020","unstructured":"Aguilera MM et al (2020) Therapeutic drug monitoring of levetiracetam in daily clinical practice: high-performance liquid chromatography versus immunoassay. Eur J Hosp Pharm 27(e1):e2\u2013e6","journal-title":"Eur J Hosp Pharm"},{"issue":"2","key":"2954_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/jrpp.JRPP_20_53","volume":"9","author":"P Ahadi","year":"2020","unstructured":"Ahadi P et al (2020) A comparative study on the efficacy of levetiracetam and carbamazepine in the treatment of rolandic seizures in children: an open-label randomized controlled trial. J Res Pharm Pract 9(2):68\u201372","journal-title":"J Res Pharm Pract"},{"issue":"2","key":"2954_CR4","first-page":"69","volume":"14","author":"J Akhondian","year":"2020","unstructured":"Akhondian J, Ashrafzadeh F, Eslamiyeh H (2020) Levetiracetam (levebel) versus carbamazepine monotherapy for focal epilepsy in children: a randomized clinical trial. Iran J Child Neurol 14(2):69","journal-title":"Iran J Child Neurol"},{"issue":"3","key":"2954_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.18295\/squmj.4.2021.002","volume":"21","author":"R Al Rajaibi","year":"2021","unstructured":"Al Rajaibi R, Al Rumhi T (2021) Carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap treated successfully with oral cyclosporin: case report and literature review. Sultan Qaboos Univ Med J 21(3):491","journal-title":"Sultan Qaboos Univ Med J"},{"key":"2954_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/B978-0-444-52891-9.00076-2","volume":"111","author":"JP Amann","year":"2013","unstructured":"Amann JP, Glauser T, Chiron C (2013) Developing antiepileptic drugs in children: balancing protection and access. Handb Clin Neurol 111:741\u2013746","journal-title":"Handb Clin Neurol"},{"issue":"10","key":"2954_CR7","first-page":"1276","volume":"41","author":"E Ben-Menachem","year":"2000","unstructured":"Ben-Menachem E, Falter U (2000) Efficacy and tolerability of levetiracetam 3000 mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group Epilepsia 41(10):1276\u20131283","journal-title":"European Levetiracetam Study Group Epilepsia"},{"issue":"12","key":"2954_CR8","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1111\/epi.16381","volume":"60","author":"E Ben-Menachem","year":"2019","unstructured":"Ben-Menachem E et al (2019) Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. Epilepsia 60(12):2437\u20132447","journal-title":"Epilepsia"},{"key":"2954_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00431-013-2125-1","volume":"173","author":"A Bertsche","year":"2014","unstructured":"Bertsche A et al (2014) Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness. Eur J Pediatr 173:87\u201392","journal-title":"Eur J Pediatr"},{"issue":"4","key":"2954_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/ph15040475","volume":"15","author":"IJ Contreras-Garc\u00eda","year":"2022","unstructured":"Contreras-Garc\u00eda IJ et al (2022) Levetiracetam mechanisms of action: from molecules to systems. Pharmaceuticals 15(4):475","journal-title":"Pharmaceuticals"},{"key":"2954_CR11","doi-asserted-by":"publisher","first-page":"107472","DOI":"10.1016\/j.yebeh.2020.107472","volume":"112","author":"C Cortes","year":"2020","unstructured":"Cortes C, Manterola C (2020) Behavioral alterations associated with levetiracetam in pediatric epilepsy. Epilepsy Behav 112:107472","journal-title":"Epilepsy Behav"},{"issue":"3","key":"2954_CR12","first-page":"276","volume":"3","author":"A Ekici","year":"2022","unstructured":"Ekici A, Yimenicio\u011flu S, Havva K (2022) Is levetiracetam monotherapy effective and safe in children with epilepsy? Eskisehir Medical Journal 3(3):276\u2013282","journal-title":"Eskisehir Medical Journal"},{"key":"2954_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-017-0758-6","volume":"17","author":"RS Fisher","year":"2017","unstructured":"Fisher RS (2017) The new classification of seizures by the International League Against Epilepsy 2017. Curr Neurol Neurosci Rep 17:1\u20136","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"2954_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","volume":"46","author":"RS Fisher","year":"2005","unstructured":"Fisher RS et al (2005) Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46(4):470\u2013472","journal-title":"Epilepsia"},{"issue":"7","key":"2954_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1517\/14656566.2016.1168399","volume":"17","author":"J Gierbolini","year":"2016","unstructured":"Gierbolini J, Giarratano M, Benbadis SR (2016) Carbamazepine-related antiepileptic drugs for the treatment of epilepsy - a comparative review. Expert Opin Pharmacother 17(7):885\u2013888","journal-title":"Expert Opin Pharmacother"},{"issue":"23","key":"2954_CR16","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1212\/WNL.0000000000001661","volume":"84","author":"DE Jung","year":"2015","unstructured":"Jung DE et al (2015) Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Neurology 84(23):2312\u20132319","journal-title":"Neurology"},{"key":"2954_CR17","volume-title":"Nelson textbook of pediatrics","author":"R Kliegmassn","year":"2015","unstructured":"Kliegmassn R, Stanton B, Geme J, Schor N, Behrman R (2015) Nelson textbook of pediatrics. Elsevier Health Sciences, New York"},{"key":"2954_CR18","unstructured":"Kumar A et al (2021) Simple partial seizure. In: StatPearls. StatPearls Publishing Copyright \u00a9 2021, StatPearls Publishing LLC.: Treasure Island (FL)"},{"key":"2954_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.seizure.2020.10.031","volume":"83","author":"V Lamouret","year":"2020","unstructured":"Lamouret V et al (2020) Is the anticonvulsant activity of levetiracetam dose-dependent? Seizure 83:197\u2013202","journal-title":"Seizure"},{"key":"2954_CR20","doi-asserted-by":"publisher","first-page":"106408","DOI":"10.1016\/j.eplepsyres.2020.106408","volume":"166","author":"R Li","year":"2020","unstructured":"Li R et al (2020) Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: an observational study in the real world. Epilepsy Res 166:106408","journal-title":"Epilepsy Res"},{"key":"2954_CR21","volume-title":"Carbamazepine","author":"JS Maan","year":"2020","unstructured":"Maan JS, Duong TVH, Saadabadi A (2020) Carbamazepine. StatPearls Publishing, Treasure Island (FL)"},{"issue":"10282","key":"2954_CR22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","volume":"397","author":"A Marson","year":"2021","unstructured":"Marson A et al (2021) The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. The Lancet 397(10282):1363\u20131374","journal-title":"The Lancet"},{"issue":"10","key":"2954_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/0883073819846804","volume":"34","author":"RD Mazur","year":"2019","unstructured":"Mazur RD et al (2019) Effectiveness of levetiracetam monotherapy in pediatric patients with epilepsy. J Child Neurol 34(10):593\u2013597","journal-title":"J Child Neurol"},{"issue":"1","key":"2954_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/0976-500X.124428","volume":"5","author":"M Mehta","year":"2014","unstructured":"Mehta M et al (2014) Anticonvulsant hypersensitivity syndrome associated with carbamazepine administration: case series. J Pharmacol Pharmacother 5(1):59\u201362","journal-title":"J Pharmacol Pharmacother"},{"key":"2954_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12028-019-00708-5","volume":"32","author":"O Morgan","year":"2020","unstructured":"Morgan O, Medenwald B (2020) Safety and tolerability of rapid administration undiluted levetiracetam. Neurocrit Care 32:131\u2013134","journal-title":"Neurocrit Care"},{"issue":"5","key":"2954_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/0883073807309784","volume":"23","author":"S Perry","year":"2008","unstructured":"Perry S, Holt P, Benatar M (2008) Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. J Child Neurol 23(5):515\u2013519","journal-title":"J Child Neurol"},{"issue":"11","key":"2954_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/01.NAJ.0000605324.61274.fe","volume":"119","author":"J Pich","year":"2019","unstructured":"Pich J (2019) Lamotrigine vs. carbamazepine monotherapy for epilepsy treatment. AJN Am J Nurs 119(11):19","journal-title":"AJN Am J Nurs"},{"key":"2954_CR28","doi-asserted-by":"publisher","first-page":"747745","DOI":"10.3389\/fneur.2021.747745","volume":"12","author":"M-Y Qiao","year":"2021","unstructured":"Qiao M-Y et al (2021) Efficacy and safety of levetiracetam vs. phenobarbital for neonatal seizures: a systematic review and meta-analysis. Front Neurol 12:747745","journal-title":"Front Neurol"},{"key":"2954_CR29","doi-asserted-by":"crossref","unstructured":"Shao W, Shen C, Wang W, Sun H, Wang X, Geng K, Wang X, Xie H\u00a0(2023) Development and validation of physiologically based pharmacokinetic model of levetiracetam to predict exposure and dose optimization in pediatrics. J Pharm Sci","DOI":"10.1016\/j.xphs.2023.03.025"},{"key":"2954_CR30","doi-asserted-by":"crossref","unstructured":"Suresh SH, Chakraborty A, Virupakshaiah A, Kumar N\u00a0(2015) Efficacy and safety of levetiracetam and carbamazepine as monotherapy in partial seizures. Epilepsy Res Treatm 2015","DOI":"10.1155\/2015\/415082"},{"key":"2954_CR31","unstructured":"Tao K et al (2022) Levetiracetam induces severe psychiatric symptoms in people with epilepsy. Seizure"},{"issue":"4","key":"2954_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1085\/jgp.201611668","volume":"149","author":"DB Tikhonov","year":"2017","unstructured":"Tikhonov DB, Zhorov BS (2017) Mechanism of sodium channel block by local anesthetics, antiarrhythmics, and anticonvulsants. J Gen Physiol 149(4):465\u2013481","journal-title":"J Gen Physiol"},{"issue":"5","key":"2954_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40263-015-0248-9","volume":"29","author":"A Weijenberg","year":"2015","unstructured":"Weijenberg A, Brouwer OF, Callenbach PM (2015) Levetiracetam monotherapy in children with epilepsy: a systematic review. CNS Drugs 29(5):371\u2013382","journal-title":"CNS Drugs"},{"issue":"5","key":"2954_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.braindev.2023.01.007","volume":"45","author":"Y Yamamoto","year":"2023","unstructured":"Yamamoto Y et al (2023) Clinical value of therapeutic drug monitoring for levetiracetam in pediatric patients with epilepsy. Brain Develop 45(5):285\u2013292","journal-title":"Brain Develop"},{"key":"2954_CR35","doi-asserted-by":"publisher","first-page":"107745","DOI":"10.1016\/j.yebeh.2020.107745","volume":"116","author":"M Y\u0131ld\u0131r\u0131m","year":"2021","unstructured":"Y\u0131ld\u0131r\u0131m M et al (2021) Levetiracetam monotherapy in children with epilepsy: experience from a tertiary pediatric neurology center. Epilepsy Behav 116:107745","journal-title":"Epilepsy Behav"},{"key":"2954_CR36","doi-asserted-by":"publisher","first-page":"109353","DOI":"10.1016\/j.yebeh.2023.109353","volume":"146","author":"R Zhou","year":"2023","unstructured":"Zhou R et al (2023) Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: a prospective study evaluating efficacy, tolerability, and behavior. Epilepsy Behav 146:109353","journal-title":"Epilepsy Behav"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-02954-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-02954-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-02954-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T09:31:29Z","timestamp":1718098289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-02954-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2954"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-02954-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3463207\/v1","asserted-by":"object"}]},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Alborz University of Medical Sciences approved this study (Approval ID:<b> IR.ABZUMS.REC.1398.208<\/b>). The Iranian Registry of Clinical Trials approved the trial by the registration number\u00a0<b>IRCT20170216032603N2<\/b> on June 19, 2020. Informed consent was obtained from the patient's parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We confirm that we have read the journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The full article was not posted or published elsewhere.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}